La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Mira Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Mira Pharmaceuticals..

Mira Pharmaceuticals (NASDAQ:MIRA) Azioni, Catena delle Opzioni

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

Miratap Inc

News

Press Releases

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

MIRA

AN2 Therapeutics

Athira Pharma

Aytu BioPharma

CalciMedica

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Curanex Pharmaceuticals Inc - Common Stock

Curanex Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Incannex Healthcare

Lexaria Bioscience

ProPhase Labs

Pulmatrix

PolyPid

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

SenesTech

Talphera

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Rodman & Renshaw

Ascendiant Capital

Screenshot 2024-10-02 at 5.44.40 PM

Biotech

General

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Comments

Mira Pharmaceuticals

Mira Pharmaceuticals (MIRA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO